Genprex Seeks Shareholder Approval for Another Reverse Stock Split (1:5 to 1:50) and Significant Equity Plan Expansion

summarizeSummary

Genprex, Inc. filed a definitive proxy statement for its annual meeting, seeking shareholder approval for a reverse stock split (1:5 to 1:50) to maintain its Nasdaq listing, following two prior reverse splits, and a substantial increase in its equity incentive plan by 1.85 million shares.

check_boxKey Events · Corporate Governance and Compliance · GNPX

• Shareholder Meeting Scheduled

  The annual meeting will be held virtually on June 18, 2026, with a record date of April 24, 2026, to vote on key corporate proposals.

• Third Reverse Stock Split Proposed

  Shareholders are asked to approve an amendment to the company's charter to effect a reverse stock split at a ratio between 1:5 and 1:50, at the Board's discretion, prior to December 31, 2027. This follows previous 1:40 (Feb 2024) and 1:50 (Oct 2025) reverse splits.

• Immediate Delisting Risk Under New Nasdaq Rules

  Given the prior reverse splits, new Nasdaq rules (5810(c)(3)(A)(iv)) indicate that if this proposed reverse split is implemented and the stock price again falls below $1.00 within one year, the company will face immediate delisting without a compliance period.

• Significant Equity Incentive Plan Expansion

  The company seeks approval to amend and restate its 2018 Equity Incentive Plan, increasing the number of shares authorized for issuance by an additional 1,850,000 shares. This represents a potential dilution of over 20% based on current outstanding shares.

auto_awesomeAnalysis · GNPX · Life Sciences

Genprex, Inc. has filed its definitive proxy statement, confirming the annual meeting on June 18, 2026, where shareholders will vote on critical proposals. The most impactful is the request for authorization to implement another reverse stock split, ranging from 1:5 to 1:50. This follows two prior reverse splits (1:40 in Feb 2024 and 1:50 in Oct 2025) aimed at maintaining Nasdaq listing. The company's stock is currently trading below the $1.00 Nasdaq minimum bid price. Under new Nasdaq rules, if this third reverse split is enacted and the stock price subsequently falls below $1.00 within a year, Genprex will face immediate delisting without a compliance period, underscoring the severe risk to its listing status. Additionally, the company proposes to significantly expand its 2018 Equity Incentive Plan by 1.85 million shares, representing a potential dilution of over 20% based on current outstanding shares, which could further pressure the stock. These proposals highlight the company's ongoing challenges in maintaining market capitalization and exchange listing.